期刊
CELLULAR SIGNALLING
卷 80, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2020.109903
关键词
Fibroblast; Angiotensin II; Fibrosis; Angiotensin converting enzyme inhibitor; Angiotensin receptor antagonist
类别
资金
- National Institutes of Health NHLBI [HL141165]
- American Heart Association [19AIREA34460000, 19POST34410055, PJT-162422]
- Canadian Institutes of Health Research (MPC)
Angiotensin II is a key mediator of profibrotic signaling in the heart, impacting cardiac function and mortality. Inhibitors of Ang II production or action, known as RAS inhibitors, are the first line therapeutics for heart failure, with potential for long-lasting effects on cardiac fibroblast responses.
Angiotensin II (Ang II) is a primary mediator of profibrotic signaling in the heart and more specifically, the cardiac fibroblast. Ang II-mediated cardiomyocyte hypertrophy in combination with cardiac fibroblast proliferation, activation, and extracellular matrix production compromise cardiac function and increase mortality in humans. Profibrotic actions of Ang II are mediated by increasing production of fibrogenic mediators (e.g. transforming growth factor beta, scleraxis, osteopontin, and periostin), recruitment of immune cells, and via increased reactive oxygen species generation. Drugs that inhibit Ang II production or action, collectively referred to as renin angiotensin system (RAS) inhibitors, are first line therapeutics for heart failure. Moreover, transient RAS inhibition has been found to persistently alter hypertensive cardiac fibroblast responses to injury providing a useful tool to identify novel therapeutic targets. This review summarizes the profibrotic actions of Ang II and the known impact of RAS inhibition on cardiac fibroblast phenotype and cardiac remodeling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据